REJURAN i

Product Overview

REJURAN i is a South Korean polynucleotide (PN) skin booster and tissue-restoration medical device manufactured by PharmaResearch Co., Ltd. Developed with a low-viscosity formulation for delicate facial skin, particularly the periorbital region, REJURAN i contains purified salmon-derived sodium polynucleotide processed using PharmaResearch's proprietary DOT™ (DNA Optimizing Technology). Manufacturer-associated documentation identifies a PN concentration of 2% (20 mg/mL), with the product supplied in a 1 mL pre-filled syringe.

REJURAN i belongs to PharmaResearch's REJURAN family of injectable polynucleotide medical devices. The product is commercially positioned for the appearance of fine wrinkles, crow's feet, and age-related changes affecting delicate skin around the eyes.

Unlike conventional cross-linked hyaluronic acid fillers, which primarily provide temporary volume through a hydrated gel, REJURAN i contains purified polynucleotides derived from salmon DNA. These materials have been investigated for their physicochemical properties and interactions with the extracellular matrix.

REJURAN i is distinguished from the original REJURAN Healer formulation by its lower viscosity and smaller syringe volume. Both products use polynucleotides, but REJURAN i is designed for more delicate tissue characteristics.

The manufacturer identifies REJURAN i as a low-viscosity PN formulation and documents a 34G × 4 mm needle with the standard 1 mL syringe presentation.

REJURAN i is part of the South Korean REJURAN tissue-restoration medical device family. Its documented regulatory intended purpose is the temporary improvement of facial wrinkles in adults.

Commercial descriptions of under-eye skin rejuvenation, hydration, elasticity, and dark-circle improvement should be distinguished from the precise indications authorized in each destination market.

This TEOSQUARE product page provides professional buyers with information about REJURAN i's composition, DOT™ technology, low-viscosity characteristics, packaging, clinical evidence, storage requirements, and regulatory considerations.

Key Features

• Purified Polynucleotide Formulation: Contains salmon-derived sodium polynucleotide (PN), with a concentration of 2% (20 mg/mL) identified in manufacturer-associated product documentation.
• Low-Viscosity Characteristics: Designed with lower viscosity than the standard REJURAN Healer formulation, supporting its commercial positioning for delicate facial skin.
• Periorbital-Focused Product: Commercially developed for the appearance of crow's feet, fine wrinkles, and age-related skin changes around the eyes.
• DOT™ Technology: Uses PharmaResearch's patented DNA Optimizing Technology to process and purify salmon-derived DNA materials.
• No Added Hyaluronic Acid: The original REJURAN i formulation is based on PN rather than an additional HA filler component.
• No Added Lidocaine: Lidocaine is not identified in the declared REJURAN i formulation, distinguishing it from REJURAN HB Plus.
• 1 mL Pre-Filled Syringe: Supplied as one 1 mL syringe per standard commercial box.
• 34G × 4 mm Needle: Manufacturer documentation identifies a fine-gauge needle as part of the product presentation.
• Room-Temperature Storage: The manufacturer specifies storage at 1–30°C with protection from light.
• South Korean Manufacturing: Manufactured by PharmaResearch, a South Korean company specializing in DNA-derived medical and aesthetic materials.

Composition & Specifications

The principal functional ingredient in REJURAN i is sodium polynucleotide, a purified DNA-derived polymer obtained from salmon.

PharmaResearch-associated product brochures and official regional brand materials identify a PN concentration of 2%, equivalent to 20 mg/mL.

Some international distributor listings instead report 1% PN. Because the manufacturer's current public product page identifies PN without specifying its concentration, the quantitative specification should be verified against the original label and instructions for use of the supplied product.

Sodium Polynucleotide (PN)

Polynucleotides are biological macromolecules composed of repeating nucleotide units connected through phosphodiester bonds.

DNA consists of polynucleotide chains responsible for storing and transmitting genetic information in living organisms.

REJURAN i contains purified DNA-derived polynucleotides obtained from salmon.

PharmaResearch processes the source material using its proprietary DOT™ technology.

The resulting polynucleotide material is incorporated into a low-viscosity injectable formulation.

Polynucleotide-based biomaterials have been investigated for their water-binding characteristics, viscoelastic properties, and interactions with the extracellular matrix.

Experimental and clinical studies have also examined their potential relationship with fibroblast-associated tissue processes and temporary wrinkle improvement.

However, these findings do not demonstrate permanent tissue regeneration or guarantee a particular clinical response to the finished REJURAN i formulation.

Documented PN Concentration — 2%

A 2% PN concentration corresponds to 20 mg of sodium polynucleotide per milliliter.

This specification appears in PharmaResearch-associated product brochures and official REJURAN regional product information.

Based on this concentration, the standard 1 mL syringe contains a nominal 20 mg of PN.

However, certain international distributor listings describe REJURAN i as containing 1% PN.

These conflicting commercial specifications should not be interpreted as proof that two officially distinct concentration variants exist.

The concentration printed on the original manufacturer-labeled product should be used to confirm the exact supplied formulation.

Polynucleotide vs. PDRN

Polynucleotide (PN) and polydeoxyribonucleotide (PDRN) are related terms used for DNA-derived nucleotide polymers.

Both may be derived from fish DNA, but their molecular-weight characteristics, formulation processes, and regulatory classifications can differ.

REJURAN i is officially described by PharmaResearch as a PN-based medical device.

It should not automatically be identified as an interchangeable formulation of a PDRN pharmaceutical injection.

Hyaluronic Acid and Lidocaine

REJURAN i is a PN-based formulation without added hyaluronic acid or lidocaine in its declared principal composition.

This distinguishes the product from REJURAN HB Plus, which combines PN with hyaluronic acid and lidocaine.

REJURAN i should therefore not be described as a conventional cross-linked HA filler or a lidocaine-containing PN booster.

REJURAN i contains sodium polynucleotide as its principal functional ingredient. The 2% (20 mg/mL) concentration is supported by manufacturer-associated materials, but conflicting third-party listings exist. Confirm the concentration against the original supplied product label before procurement or publication of batch-specific specifications.

DOT™ — DNA Optimizing Technology

REJURAN i is manufactured using PharmaResearch's proprietary DOT™ technology.

DOT™ stands for DNA Optimizing Technology, a patented process developed for the extraction, purification, and optimization of DNA-derived materials.

Salmon-Derived DNA

PharmaResearch obtains DNA-derived raw materials from salmon.

The source material undergoes specialized processing before being incorporated into the finished medical device.

Salmon-derived polynucleotides are used in the REJURAN product family because of their material characteristics and established research interest in DNA-derived biomaterials.

DNA Extraction and Purification

DOT™ technology is intended to produce highly purified polynucleotide materials with controlled characteristics.

The manufacturing process involves specialized extraction, purification, and material optimization.

These steps are relevant to the quality and consistency of DNA-derived medical materials.

However, a patented purification method does not independently establish the complete absence of impurities, hypersensitivity reactions, or other complications.

Optimized Material Characteristics

The physical properties of PN formulations depend on factors such as polymer concentration, molecular-weight distribution, and formulation characteristics.

REJURAN i is developed with lower viscosity than the standard REJURAN Healer formulation.

This difference contributes to its commercial positioning for delicate facial skin.

The precise molecular-weight distribution and full physicochemical specifications should be confirmed from manufacturer-controlled technical documentation.

DOT™ is a proprietary manufacturing technology rather than an additional active ingredient. Its use does not independently establish superior clinical effectiveness or guaranteed skin regeneration.

Low-Viscosity Formulation for Delicate Skin

A defining characteristic of REJURAN i is its low-viscosity formulation.

PharmaResearch differentiates the REJURAN range using formulation viscosity, syringe volume, and commercial treatment positioning.

Understanding Viscosity

Viscosity describes a material's resistance to flow.

A relatively low-viscosity formulation generally flows more readily under comparable testing conditions than a higher-viscosity formulation.

Viscosity is relevant to the physical handling characteristics of injectable PN products.

REJURAN i vs. REJURAN Healer

The manufacturer classifies standard REJURAN Healer as a medium-viscosity product.

REJURAN i is classified as low viscosity.

This difference is relevant to the product's commercial positioning for thinner and more delicate skin.

It should not be interpreted as proof that REJURAN i produces no swelling, papules, nodules, or other local reactions.

Periorbital-Focused Formulation

The periorbital region includes delicate skin surrounding the eyes.

This area has distinctive anatomical characteristics, including relatively thin skin and complex vascular structures.

REJURAN i is commercially positioned for fine wrinkles and other age-related skin concerns affecting this region.

Its lower viscosity is one of the manufacturer's principal distinguishing characteristics.

However, suitability for a particular anatomical location must be determined by the approved product labeling and qualified healthcare professionals.

34G Needle Presentation

Manufacturer documentation identifies a 34G × 4 mm needle with the standard REJURAN i presentation.

The needle specification helps distinguish REJURAN i from other members of the REJURAN product family.

This specification is provided for product identification rather than as a recommendation for administration technique.

Low viscosity and fine-gauge needle presentation are product characteristics. They do not eliminate discomfort, injection-related complications, or the need for appropriate professional medical assessment.

How REJURAN i Works

REJURAN i is based on purified polynucleotides that have been investigated for their interactions with biological tissues and the extracellular matrix.

Its formulation differs from cross-linked HA fillers primarily designed to provide structural volume.

Polynucleotides and the Extracellular Matrix

The extracellular matrix is a network of biological molecules surrounding cells.

It contains collagen, elastin, glycosaminoglycans, and other components that contribute to tissue structure and function.

Polynucleotides are DNA-derived polymer chains with physicochemical properties that have been investigated in relation to the extracellular environment.

These characteristics provide a scientific basis for studying PN-based materials in tissue-restoration applications.

Water-Binding Properties

Polynucleotide chains contain chemical groups capable of interacting with water.

These properties contribute to the behavior of PN-containing aqueous formulations.

REJURAN i is commercially associated with hydration-related improvements in delicate facial skin.

However, the presence of PN does not independently establish a specific increase in skin moisture or a guaranteed improvement in under-eye dryness.

Fibroblast-Associated Tissue Processes

Fibroblasts are connective tissue cells involved in producing collagen and other extracellular matrix components.

Experimental investigations of polynucleotide-based materials have examined their effects on fibroblast-associated biological processes.

These findings provide a scientific rationale for studying polynucleotides in tissue-restoration and aesthetic applications.

However, findings from cell studies and other PN products do not establish a predictable amount of collagen formation following REJURAN i treatment.

Temporary Facial Wrinkle Improvement

REJURAN i belongs to a medical device family intended for temporary improvement of facial wrinkles in adults.

The product's low-viscosity formulation is commercially positioned for fine wrinkles in delicate areas, particularly crow's feet.

Clinical outcomes depend on individual characteristics, the exact formulation, and the circumstances of authorized professional use.

These mechanisms describe established material properties and scientific research involving polynucleotides. They do not guarantee permanent skin regeneration, a specific degree of wrinkle reduction, or long-term clinical effects.

Clinical Research & Evidence

Polynucleotide-based aesthetic devices have been evaluated in clinical research involving facial and periorbital wrinkles.

Evidence concerning REJURAN i should be distinguished from studies involving the original REJURAN formulation or different PN products.

Clinical Research on Crow's Feet

A randomized, double-blind clinical trial published in 2014 investigated a 20 mg/mL REJURAN polynucleotide formulation for crow's-feet correction.

The study enrolled 72 participants and compared the PN formulation with a non-crosslinked hyaluronic acid preparation.

The investigators reported that the PN formulation met the study's non-inferiority criteria for the primary wrinkle-improvement outcome.

However, the clinical efficacy outcomes did not establish statistically significant superiority over the HA comparator.

Importantly, the study identified the investigational product as REJURAN rather than specifically confirming the later REJURAN i presentation.

Therefore, its findings provide background evidence for the REJURAN PN platform but should not automatically be presented as a product-specific clinical trial of REJURAN i.

Research Specifically Involving REJURAN i

A randomized, patient-blinded, split-face clinical study published in 2026 used REJURAN i as a conventional PN comparator when investigating a modified PN formulation.

The study enrolled 15 participants with periorbital wrinkles.

Investigators assessed injection discomfort, wrinkle-related outcomes, and local adverse reactions.

The study provides directly relevant evidence that REJURAN i has been used as a reference product in controlled clinical research involving crow's feet.

However, its small sample size and comparative design limit the conclusions that can be drawn about long-term effectiveness and broader clinical safety.

Research Limitations

Clinical studies of PN-based products differ in formulation, treatment conditions, participant characteristics, follow-up duration, and outcome measures.

Findings involving the original REJURAN formulation, other PN products, or combination procedures should not automatically be attributed to REJURAN i.

The available evidence does not establish guaranteed elimination of under-eye wrinkles, correction of dark circles from every cause, permanent skin thickening, or predictable long-term volume restoration.

Clinical findings should be interpreted according to the exact product, study population, and measured outcomes. REJURAN i's documented intended purpose concerns temporary facial wrinkle improvement, not permanent rejuvenation.

Professional Aesthetic Positioning

REJURAN i is commercially positioned as a low-viscosity PN product for delicate facial skin.

The manufacturer and professional distributors particularly associate the product with the periorbital region.

Crow's Feet

Crow's feet are fine lines and wrinkles that develop around the outer corners of the eyes.

Their appearance can be influenced by facial movement, skin aging, sun exposure, and changes in dermal structure.

REJURAN i is commercially positioned for temporary improvement of the appearance of these wrinkles.

Fine Under-Eye Wrinkles

The skin beneath the eyes is relatively thin and can develop visible fine lines as its structure changes with age.

REJURAN i's low-viscosity characteristics support its commercial positioning for delicate skin.

The degree of clinical improvement depends on individual anatomy, product characteristics, and authorized treatment conditions.

Skin Texture and Hydration

REJURAN i is also marketed for improving the appearance of skin texture and dryness-related changes around the eyes.

Polynucleotide materials possess water-binding characteristics and have been studied in relation to tissue-restoration processes.

However, these properties do not independently establish a measurable or guaranteed improvement in skin hydration.

Dark Circles and Under-Eye Appearance

Dark circles can arise from several different causes, including pigmentation, vascular visibility, facial anatomy, and shadowing associated with volume changes.

Commercial descriptions sometimes associate REJURAN i with improvement in the appearance of dark circles.

However, REJURAN i should not be described as a clinically established treatment for every cause of periorbital pigmentation or shadowing.

Under-Eye Volume Concerns

REJURAN i is not a conventional cross-linked HA volumizing filler.

Its PN-based formulation and low viscosity distinguish it from products primarily designed for structural augmentation.

The product should not be promoted as a guaranteed replacement for anatomical volume restoration or correction of pronounced tear-trough deformities.

These applications describe REJURAN i's commercial positioning. The approved indications and permitted anatomical applications must be determined from the current instructions for use and destination-country regulations.

REJURAN i vs. Other REJURAN Products

PharmaResearch offers several PN-based medical devices within the REJURAN family.

They differ in formulation viscosity, syringe volume, and commercial positioning.

*The REJURAN i 2% PN concentration is documented in manufacturer-associated brochures and official regional brand materials. Some third-party listings report 1%; verify the exact supplied product label.

REJURAN Healer

REJURAN Healer is the original medium-viscosity PN formulation within the product family.

It is supplied as two 2 mL syringes and is commercially positioned for general facial wrinkle improvement and skin-quality concerns.

REJURAN i

REJURAN i is the low-viscosity formulation commercially developed for delicate facial skin.

It is supplied as one 1 mL syringe with a documented 34G × 4 mm needle.

The formulation is particularly associated with fine wrinkles around the eyes.

REJURAN s

REJURAN s is a higher-viscosity PN formulation commercially positioned for selected scar-related aesthetic concerns.

It is supplied as one 1 mL syringe.

Its higher viscosity differentiates it from REJURAN i.

REJURAN HB Plus

REJURAN HB Plus is a separate formulation combining polynucleotides, hyaluronic acid, and lidocaine.

Its HA and lidocaine components distinguish it from the PN-only REJURAN i formulation.

This page covers REJURAN i only. The material characteristics and approved indications of other REJURAN products should not automatically be applied to REJURAN i.

Packaging & Product Presentation

REJURAN i is supplied as a sterile PN preparation in a pre-filled syringe.

The standard manufacturer-documented packaging configuration contains one 1 mL syringe per box.

1 mL Pre-Filled Syringe

Each REJURAN i syringe contains a nominal 1 mL of the PN-based preparation.

The product is supplied in pre-filled form rather than as a dry powder requiring reconstitution.

The manufacturer documents low viscosity as a defining formulation characteristic.

34G × 4 mm Needle

The standard product presentation includes a documented 34G × 4 mm needle.

This needle specification is associated with the product's commercial positioning for delicate skin.

The needle details are provided for product identification rather than as clinical administration instructions.

One-Syringe Commercial Box

The standard documented manufacturer package contains one pre-filled syringe.

Some distributors may offer multiple-syringe purchasing quantities, but these should not be confused with the original manufacturer packaging.

Product Authentication

PharmaResearch has introduced authentication features for selected REJURAN packaging to help address counterfeit products and unauthorized distribution.

Buyers should verify the original manufacturer labeling, batch number, expiration date, and available product authentication features.

The verified standard presentation is 1 mL × 1 syringe per box, with a documented 34G × 4 mm needle. Confirm all packaging and concentration specifications against the supplied product.

Storage & Handling

PharmaResearch specifies room-temperature storage between 1°C and 30°C for REJURAN i.

The product should be protected from light and maintained according to its original manufacturer-issued instructions for use.

• Storage Temperature: Store unopened syringes between 1°C and 30°C.
• Light Protection: Protect the product from direct sunlight and inappropriate light exposure.
• Freezing Protection: Avoid freezing the product.
• Original Packaging: Maintain the syringe in its original manufacturer packaging.
• Sterile Barrier Integrity: Do not use products with damaged packaging or evidence of compromised sterility.
• Single-Patient Use: Follow the manufacturer's instructions for sterile handling and disposal.
• Product Traceability: Confirm the product name, batch number, expiration date, and manufacturer information.

Shelf Life

Product registration and commercial documentation identify a shelf life of 24 months for REJURAN i.

The expiration date printed on the supplied product takes precedence over general catalogue specifications.

REJURAN i's documented storage conditions are 1–30°C with protection from light. Do not substitute the refrigerated storage requirements of other REJURAN formulations.

Safety & Regulatory Considerations

REJURAN i is an injectable PN-based medical device intended for use by appropriately qualified healthcare professionals.

Professional use requires consideration of the patient's medical history, known allergies, individual anatomy, contraindications, and the potential complications associated with injectable medical devices.

Potential Adverse Reactions

Potential adverse reactions associated with PN injections include localized discomfort, redness, swelling, bruising, tenderness, and temporary papules at the administration site.

Other possible complications include infection, hypersensitivity reactions, inflammatory responses, and persistent tissue irregularities.

The presence of a low-viscosity formulation does not eliminate these risks.

Periorbital Safety Considerations

The periorbital region contains delicate skin and important vascular structures.

Injectable treatments near the eyes require particular attention to anatomical safety.

Accidental introduction of injectable material into a blood vessel can cause serious complications.

The manufacturer's commercial positioning for the eye area does not establish that every periorbital location or administration approach is authorized or safe.

Salmon-Derived Ingredients

REJURAN i contains polynucleotides derived from salmon DNA.

Patients with relevant hypersensitivity histories, including known reactions to fish-derived substances or formulation components, require appropriate clinical assessment.

Manufacturing purification does not establish that hypersensitivity reactions are impossible.

Contraindications and Precautions

Relevant contraindications and precautions include known hypersensitivity to formulation components, active infection or inflammation affecting the intended treatment area, and certain underlying medical conditions.

Patients receiving anticoagulants, antiplatelet medicines, immunosuppressants, or other treatments affecting procedural risk may require additional evaluation.

Product-specific restrictions concerning pregnancy, breastfeeding, pediatric patients, and previous injectable treatments should be determined from the current manufacturer-issued instructions for use.

South Korean Medical Device Authorization

REJURAN i belongs to the PharmaResearch REJURAN medical device family registered in South Korea.

The original REJURAN family received South Korean medical device authorization in 2014, with additional models introduced subsequently.

REJURAN i is identified as a tissue-restoration medical device intended for temporary improvement of facial wrinkles in adults.

Commercial claims concerning under-eye bags, dark circles, skin brightening, or permanent regeneration should not automatically be treated as approved medical indications.

International Regulatory Considerations

REJURAN i is distributed internationally through professional medical aesthetics channels.

Product-specific regulatory authorization exists in selected international markets, including Thailand and Argentina.

However, authorization remains specific to each country, formulation, product presentation, and approved intended purpose.

US FDA approval for injectable REJURAN i has not been established.

South Korean authorization or approval in another country does not automatically permit importation, distribution, or administration in the United States.

Professional buyers should verify the current product registration, authorized indications, labeling, import eligibility, and lawful distribution requirements in their destination market.

This information is intended for professional product identification and commercial evaluation. It does not provide injection instructions, establish individual patient suitability, or authorize use outside applicable medical device regulations.

Frequently Asked Questions